Impact on Quality of Life of "Endo-App" (ELEA) (ELEA)
Primary Purpose
Endometriosis, Endometriosis-related Pain, Quality of Life
Status
Active
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Use of Endo App
Sponsored by
About this trial
This is an interventional treatment trial for Endometriosis focused on measuring endometriosis, quality of life, Endo-App, EHP-5, Endometriosis Health Profile, digital therapeutics
Eligibility Criteria
Inclusion Criteria:
- endometriosis histologically proven
- no operation or medical treatment currently performed or planned
- capable of using a smartphone
- willingness to use a smartphone and the Endo App
Exclusion Criteria:
- absence of inclusion criteria
Sites / Locations
- University Hospital Münster Germany
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Endo App use
control
Arm Description
use of Endo App during trial
no use of Endo App during trial
Outcomes
Primary Outcome Measures
EHP 5
Change in Endometriosis Health Profile 5 (minimum value: 0 points, maximum value: 100 points, higher scores mean a worse outcome)
Secondary Outcome Measures
FSS survey
Change over course of study
FESS survey
Change over course of study
PDI survey
Change over course of study
DASS-21 survey
Change over course of study
EHP 5
Change between 1st and 2nd survey
EHP 5
Change between 1st and 3rd survey
Full Information
NCT ID
NCT04883073
First Posted
May 6, 2021
Last Updated
January 25, 2023
Sponsor
University Hospital Muenster
Collaborators
Endo Health GmbH
1. Study Identification
Unique Protocol Identification Number
NCT04883073
Brief Title
Impact on Quality of Life of "Endo-App" (ELEA)
Acronym
ELEA
Official Title
Impact on Quality of Life by Additional Use of the Digital Health Application "Endo-App" to Standard Therapy: Monocentric, Prospective, Randomised Trial (ELEA)
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 13, 2023 (Actual)
Primary Completion Date
July 2023 (Anticipated)
Study Completion Date
September 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital Muenster
Collaborators
Endo Health GmbH
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
monocentric randomized controlled trial enrolment of endometriosis patients from certified endometriosis centers. Randomization to control group (no Endo App use) vs intervention group (Endo App use) 12 weeks use / no use of Endo App. Evaluation of quality of life at onset, at 4, 8 and 12 weeks by using endometriosis health profile (EHP) 5 as a global index. Statistical analysis of global index at the end minus global index at onset between control and intervention group.
Detailed Description
randomized controlled trial enrolment of patients with diagnosed endometriosis 300 patients in total, 150 patients per group, randomization to control group (no Endo App use) vs intervention group (12 weeks Endo App use). The Endo App is a german language certified medical device which can be used to monitor the disease and gives support by providing complementary, multimodal interventions to standard therapy and is commercially available. Purpose of this study is the evaluation of quality of life at onset and then at 4, 8 and 12 weeks by using endometriosis health profile (EHP) 5 as a global index. The secondary endpoints of this study to evaluate are Fatigue symptoms (FSSsurvey), pain- specific self-efficacy (FESS), difficulty in everyday life due to pain (PDI) and emotional wellbeing (DASS- 21)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometriosis, Endometriosis-related Pain, Quality of Life
Keywords
endometriosis, quality of life, Endo-App, EHP-5, Endometriosis Health Profile, digital therapeutics
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
monocentric single side blinded randomized controlled trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Endo App use
Arm Type
Experimental
Arm Description
use of Endo App during trial
Arm Title
control
Arm Type
No Intervention
Arm Description
no use of Endo App during trial
Intervention Type
Device
Intervention Name(s)
Use of Endo App
Intervention Description
Use of Endo App
Primary Outcome Measure Information:
Title
EHP 5
Description
Change in Endometriosis Health Profile 5 (minimum value: 0 points, maximum value: 100 points, higher scores mean a worse outcome)
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
FSS survey
Description
Change over course of study
Time Frame
12 weeks
Title
FESS survey
Description
Change over course of study
Time Frame
12 weeks
Title
PDI survey
Description
Change over course of study
Time Frame
12 weeks
Title
DASS-21 survey
Description
Change over course of study
Time Frame
12 weeks
Title
EHP 5
Description
Change between 1st and 2nd survey
Time Frame
4 weeks
Title
EHP 5
Description
Change between 1st and 3rd survey
Time Frame
8 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Legal capacity
Living in Germany
Adequate german language skills
Female biological gender
Ages eligible for study ≥ 18 years
Medical Diagnosis of endometriosis
Diagnosis verification by following documents:
Operation Report
Histological finding
MRI finding
Other medical examination documents with endometriosis diagnosis (for example sonography, colonoscopy, cystoscopy)
Owning a smartphone and having an internet access
Willingness and capability of using the smartphone device and the Endo App
Motivation to regularly fill out the questionnaries
Owning an e-mail address for App registration
Absence of exlusion criteria
Exclusion Criteria:
Absence of inclusion criteria
Pregnancy existing at survey period
Ongoing hormonal fertility treatment or planned treatment within the next 12 weeks (artificial insemination as part of in vitro fertilization, such as IVF or ICSI, hormone injections for fertility treatment)
Ongoing or within the next 12 weeks planned rehabilitation or multimodal pain therapy
Planned change in hormone therapy (change of active substance, new start or discontinuation of therapy) in the next 12 weeks or change in hormone therapy within the last 8 weeks before the start of the study
Endometriosis surgery planned in the next 12 weeks or endometriosis surgery performed within the last 8 weeks prior to study start
Previous or existing access to Endo app or current prescription
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sebastian D Schäfer, MD PhD
Organizational Affiliation
University Hospital Münster, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Münster Germany
City
Münster
State/Province
NRW
ZIP/Postal Code
48149
Country
Germany
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Impact on Quality of Life of "Endo-App" (ELEA)
We'll reach out to this number within 24 hrs